Interleukin-11 Human Recombinant ( IL 11 Human )

Catalog # PT_41136

Print

$201.00
DescriptionInterleukin-11 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 179 amino acids and having a molecular mass of 19256.29 Dalton. The IL-11 is purified by proprietary chromatographic
Product Size: 2ug
Quantity

Data sheet

Formulation
The protein was lyophilized from a concentrated (1mg/ml) solution with no additives.
Solubility
It is recommended to reconstitute the lyophilized Interleukin 11 in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
Purity
Greater than 98.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.
Description
Interleukin-11 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 179 amino acids and having a molecular mass of 19256.29 Dalton. The IL-11 is purified by proprietary chromatographic techniques.
Protein Background
IL11 is a member of the gp130 family of cytokines. These cytokines drive the assembly of multisubunit receptor complexes, all of which contain at least one molecule of the transmembrane signaling receptor IL6ST (gp130). IL-11 is shown to stimulate the T-c
Expression host
Escherichia Coli.
Synonyms
AGIF, Adipogenesis inhibitory factor, Oprelvekin, IL-11.
Reagent Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Stability
Lyophilized Interleukin-11 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IL11 should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended t
Amino acid sequence
The sequence of the first five N-terminal amino acids was determined and was found to be Gly-Pro-Pro-Pro-Gly. N-terminal methionine has been completely removed enzymatically.
Biological Activity
The ED50 as determined by the dose-dependant stimulation of the proliferation of murine 7TD1 was found to be
References
Title: Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients Publication: PloS one 4.8 (2009): e6745. Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.000674
Immunological Activity
Thimerosal and beta propiolactone treatmentThis product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are requ
Reference
Tested with anti-influenza B monoclonal antibodies in ELISA.Serological studies of influenza B virus, immunogen for antibody production.
New